
New toxin accepted for review
Biopharmaceutical company Hugel America and aesthetic manufacturer Croma-Pharma has unveiled that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for letibotulinumtoxinA as a treatment for glabellar lines.









